Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) just unveiled an announcement.
China Resources Pharmaceutical Group Ltd. announced the proposed formation of a joint venture fund, the China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership, with a proposed size of RMB1 billion. The fund aims to engage in equity investment and venture capital activities, focusing on pharmaceutical and health industries, as well as strategic emerging sectors. This initiative is expected to help the company manage risks in mergers and acquisitions, ensure the quality of target companies, and accelerate strategic mergers and acquisitions to achieve its long-term goals.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products, including chemical innovative drugs, biological drugs, high-end medical devices, traditional Chinese medicine, and more. The company is involved in strategic investments and mergers to enhance its position in the pharmaceutical and health sectors.
Average Trading Volume: 8,859,447
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.17B
For detailed information about 3320 stock, go to TipRanks’ Stock Analysis page.